In advanced NSCLC patients with EGFR mutation, combining antiangiogenic agents with EGFR‐TKIs significantly increased the PFS compared to treatment with EGFR‐TKIs alone (HR = 0.60, 95% CI: 0.52–0.69, p < 0.001) (Figure S1A, Table S1). This evidence concerns the gene EGFR and non-small cell lung carcinoma.